Head-To-Head Analysis: Collegium Pharmaceutical (COLL) versus Neos Therapeutics (NEOS)

Collegium Pharmaceutical (NASDAQ: COLL) and Neos Therapeutics (NASDAQ:NEOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider & Institutional Ownership

80.0% of Collegium Pharmaceutical shares are owned by institutional investors. Comparatively, 45.8% of Neos Therapeutics shares are owned by institutional investors. 25.8% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 5.2% of Neos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Collegium Pharmaceutical has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Neos Therapeutics has a beta of -0.74, suggesting that its share price is 174% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Collegium Pharmaceutical and Neos Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical 0 0 5 0 3.00
Neos Therapeutics 0 0 5 0 3.00

Collegium Pharmaceutical currently has a consensus price target of $24.80, suggesting a potential upside of 30.12%. Neos Therapeutics has a consensus price target of $16.20, suggesting a potential upside of 62.81%. Given Neos Therapeutics’ higher possible upside, analysts clearly believe Neos Therapeutics is more favorable than Collegium Pharmaceutical.

Earnings & Valuation

This table compares Collegium Pharmaceutical and Neos Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Collegium Pharmaceutical $1.71 million 362.92 -$94.17 million ($2.98) -6.40
Neos Therapeutics $9.15 million 31.54 -$83.33 million ($3.42) -2.91

Neos Therapeutics has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Neos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Collegium Pharmaceutical and Neos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical -447.83% -77.11% -61.94%
Neos Therapeutics -339.52% -551.26% -68.57%

Summary

Collegium Pharmaceutical beats Neos Therapeutics on 7 of the 12 factors compared between the two stocks.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

What are top analysts saying about Collegium Pharmaceutical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit